Home > Cardiology > AHA 2020 > CVD Risk Reduction > Safety and efficacy of inclisiran for hypercholesterolemia

Safety and efficacy of inclisiran for hypercholesterolemia

Presented By
Prof. R. Scott Wright, Mayo Clinic, USA
AHA 2020
Phase 3, ORION
Three placebo-controlled phase 3 trials have evaluated the efficacy and safety of inclisiran. Inclisiran lowered low-density lipoprotein (LDL) cholesterol similarly across all ages with an acceptable safety profile [1]. The efficacy and safety profile of inclisiran was generally similar in both sexes [2]. Prof. R. Scott Wright (Mayo Clinic, USA) presented the results of 2 pooled analyses evaluating the efficacy and safety of inclisiran according to age and sex, respectively. Both analyses included data from three phase 3 placebo-controlled trials: ORION-9 in patients with heterozygous familial hypercholesterolaemia (HeFH); ORION-10 in patients with atherosclerotic cardiovascular disease (ASCVD); and ORION-11 in patients with ASCVD or ASCVD risk equivalents. In the first analysis, a total of 3,660 patients were categorised according to age: <65 yea...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on